The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of AstraZeneca's 2013 sales performance.
AstraZeneca's (AZ) Imfinzi (durvalumab) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat biliary tract cancer (BTC) in combination with chemotherapy, the company announced. ... AstraZeneca’s application for
The company then suffered another major blow earlier this year when poor late-stage trial results for an antidepressant candidate abruptly brought about the end of its collaboration with AstraZeneca.
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been recommended by the National Institute for Health and Care Excellence (NICE) for the treatment of HER2-positive unresectable or metastatic breast.
AstraZeneca (AZ) and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved by the European Commission (EC) to treat unresectable or metastatic HER2-low breast cancer.
The guide was co-authored by leading experts from Roche, AstraZeneca and others. ... The guide was co-authored by the Pistoia Alliance and leading experts in the field, which included AstraZeneca, Roche, Bayer, Genentech, Galapagos, the Hyve, Elixir, the
A leading global patient-activation group - comprising of a digital insight consultancy, creative activation agency. Our foundations lie in behavioural...